Complexing agents for compositions containing inclusion complexes

Abstract

The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. The invention also relates to a method of preparing a composition of the present disclosure. The invention further relates to a method of delivering a therapeutic agent, using the composition of the present disclosure, where a therapeutically effective amount of a therapeutic composition of the invention may be administered to a mammal (e.g. person or animal) in recognized need of the therapeutic.

1 - 10 . (canceled) 
     
     
         11 . A method of preparing a PEG-terminated β-cyclodextrin-DMS copolymer, comprising:
 a. providing a β-cyclodextrin(cystamine)-DMS copolymer in a solution; 
 b. adding FMOC-PEG-NHS to the solution; 
 c. lyophilizing the solution to generate a solid; 
 d. dissolving the solid, thereby resulting in FMOC deprotection; 
 e. removing solvent to generate a viscous liquid; 
 f. separating the copolymer from unreacted PEG by anion exchange chromatography; and 
 g. recovering the copolymer. 
 
     
     
         12 . The method of  claim 11 , wherein the FMOC-PEG-NHS is FMOC-PEG 3400 -NHS. 
     
     
         13 . The method of  claim 11 , wherein the solution further comprises NaHCO 3 . 
     
     
         14 . The method of  claim 11 , wherein the solid is dissolved in a solution of piperidine in DMF.